GENB.O (GENB.O) News
Follow GENB.O (GENB.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
UPDATE 1 — Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion
(Updates sourcing, adds details throughout) Oct 13 (Reuters) — Zealand Pharma and Generate Biomedicines said on Tuesday they have partnered to develop protein-based treatments for obesity and other metabolic diseases usi
EQUITY | Oct 13, 2026, 09:07 PM UTC
L
BRIEF — Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Generate Biomedicines Inc: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases Generate Biomedicines - To Receive $
NEWS | Oct 13, 2026, 08:36 PM UTC
L
Generate Biomedicines partners with Zealand Pharma to develop AI — designed protein therapeutics for metabolic diseases
Generate Biomedicines entered a multi-target collaboration with Zealand Pharma to develop AI-engineered multispecific protein therapeutics for obesity. Agreement targets obesity and other metabolic diseases, combining Ze
NEWS | Oct 13, 2026, 08:32 PM UTC
L
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Oct 13 (Reuters) — Danish drugmaker Zealand Pharma and Generate Biomedicines have struck a deal worth up to nearly $1.2 billion to develop obesity treatments using artificial intelligence, Bloomberg News reported on Tues
NEWS | Oct 13, 2026, 08:30 PM UTC